Cimetidine was first marketed in the United Kingdom in 1976, and in the . in August 1977; therefore, it took 12 years from initiation of the H 2 receptor antagonist program to commercialization. By 1979, Tagamet was being sold in more than 100 countries and became the top-selling prescription product in the ., Canada, and several other countries. In November 1997, the American Chemical Society and the Royal Society of Chemistry in the . jointly recognized the work as a milestone in drug discovery by designating it an International Historic Chemical Landmark during a ceremony at SmithKline Beecham's New Frontiers Science Park research facilities in Harlow, England. 
Flutamide acts as a selective, competitive , silent antagonist of the androgen receptor (AR).  Its active metabolite , 2-hydroxyflutamide , has between 10- to 25-fold higher affinity for the AR than does flutamide, and hence is a more powerful antiandrogen in comparison.     However, at high concentrations, unlike flutamide, 2-hydroxyflutamide is able to weakly activate the AR.   Flutamide has far lower affinity for the AR than do steroidal antiandrogens like spironolactone and cyproterone acetate, and it is a relatively weak antiandrogen in terms of potency by weight, but the large dosages at which flutamide is used appear to compensate for this.  In accordance with its selectivity for the AR, flutamide possesses no progestogenic , (direct) estrogenic , glucocorticoid , or antigonadotropic activity.   Similarly to nilutamide, bicalutamide, and enzalutamide , flutamide crosses the blood-brain-barrier and exerts central antiandrogen actions.